Shares in Bruker BioSciences and Stratagene both declined more than 5 percent for the tracking period ended Tuesday, leading the way among the 10 companies in the BCW Index whose shares declined during the period. Stratagene's shares dropped 7.22 percent, far exceeding the 5.59-percent gain registered the week before, while shares in Bruker dropped 5.32 percent, giving back part of its 9.89-percent gain last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.